Long-Term Implantable Glucose Monitoring Systems: Regulatory Strategy for FDA Premarket Approval and Global Market Access
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Long-term implantable continuous glucose monitoring systems represent an innovative approach to diabetes management, utilizing subcutaneously implanted sensors capable of monitoring glucose levels for extended periods of up to 180 days. These systems address limitations of conventional short-term CGM sensors that require frequent replacement, improving patient convenience and potentially enhancing monitoring adherence. The implantable sensor design introduces unique regulatory considerations including surgical implantation and removal procedures, long-term biocompatibility, and tissue-sensor interface stability over extended wear periods. As implantable diagnostic devices where erroneous readings could result in inappropriate therapeutic decisions with serious consequences, these systems are classified as Class III devices requiring FDA Premarket Approval (PMA). This article examines the regulatory framework for long-term implantable CGM systems, including classification rationale, applicable standards, clinical evidence requirements, and strategic pathways for market authorization. Keywords: implantable glucose monitor, fluorescence sensing, Class III medical device, PMA, diabetes mellitus, long-term monitoring, FDA, Health Canada, ISO 13485
Fields of Study & Subjects
Healthcare Regulation
Diabetes Management and Research
Electrochemical sensors and biosensors
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 25 March 2026
- Language
- EN